Page 64 - Read Online

Murray LJ, Heinrich MC, Cherrington JM. SU11248 is a novel Cancer Res 2004;64:7099-109.
FLT3 tyrosine kinase inhibitor with potent activity in vitro and in 127. Wilhelm SM, Dumas J, Adnane L, Lynch M, Carter CA, Schütz G,
vivo. Blood 2003;101:3597-605. Thierauch KH, Zopf D. Regorafenib (BAY 73-4506): a new oral
115. Faivre S, Delbaldo C, Vera K, Robert C, Lozahic S, Lassau N, multikinase inhibitor of angiogenic, stromal and oncogenic receptor
Bello C, Deprimo S, Brega N, Massimini G, Armand JP, Scigalla tyrosine kinases with potent preclinical antitumour activity. Int J
P, Raymond E. Safety, pharmacokinetic, and antitumor activity Cancer 2011;129:245-55.
of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in 128. Bill R, Fagiani E, Zumsteg A, Antoniadis H, Johansson D,
patients with cancer. J Clin Oncol 2006;24:25-35. Haefliger S, Albrecht I, Hilberg F, Christofori G. Nintedanib Is a
116. Kulke MH, Lenz HJ, Meropol NJ, Posey J, Ryan DP, Picus J, Highly Effective Therapeutic for Neuroendocrine Carcinoma of the
Bergsland E, Stuart K, Tye L, Huang X, Li JZ, Baum CM, Fuchs Pancreas (PNET) in the Rip1Tag2 Transgenic Mouse Model. Clin
CS. Activity of sunitinib in patients with advanced neuroendocrine Cancer Res 2015;21:4856-67.
tumours. J Clin Oncol 2008;26:3403-10. 129. Bago-Horvath Z, Sieghart W, Grusch M, Lackner A, Hayden H,
117. Raymond E, Dahan L, Raoul JL, Bang YJ, Borbath I, Lombard- Pirker C, Komina O, Węsierska-Gądek J, Haitel A, Filipits M,
Bohas C, Valle J, Metrakos P, Smith D, Vinik A, Chen JS, Hörsch Berger W, Schmid K. Synergistic effects of erlotinib and everolimus
D, Hammel P, Wiedenmann B, Van Cutsem E, Patyna S, Lu DR, on bronchial carcinoids and large-cell neuroendocrine carcinomas
Blanckmeister C, Chao R, Ruszniewski P. Sunitinib malate for the with activated EGFR/AKT/ mTOR pathway. Neuroendocrinology
treatment of pancreatic neuroendocrine tumours. N Engl J Med 2012;96:228-37.
2011;364:501-13. 130. Shah T, Hochhauser D, Frow R, Quaglia A, Dhillon AP, Caplin
118. Yao JC, Phan AT, Hoff PM, Chen HX, Charnsangavej C, Yeung ME. Epidermal growth factor receptor expression and activation in
SC, Hess K, Ng C, Abbruzzese JL, Ajani JA. Targeting vascular neuroendocrine tumours. J Neuroendocrinol 2006;18:355-60.
endothelial growth factor in advanced carcinoid tumour: a random 131. Papouchado B, Erickson LA, Rohlinger AL, Hobday TJ, Erlichman
assignment phase II study of depot octreotide with bevacizumab C, Ames MM, Lloyd RV. Epidermal growth factor receptor
and pegylated interferon alpha-2b. J Clin Oncol 2008;26,1316-23. and activated epidermal growth factor receptor expression in
119. Faivre S, Sablin MP, Dreyer C, Raymond E. Novel anticancer gastrointestinal carcinoids and pancreatic endocrine carcinomas.
agents in clinical trials for well-differentiated neuroendocrine Mod Pathol 2005;18:1329-35.
tumours. Endocrinol Metab Clin North Am 2010;39:811-26. 132. Srivastava A, Alexander J, Lomakin I, Dayal Y.
120. Chan JA, Stuart K, Earle CC, Clark JW, Bhargava P, Miksad R, Immunohistochemical expression of transforming growth factor
Blaszkowsky L, Enzinger PC, Meyerhardt JA, Zheng H, Fuchs CS, alpha and epidermal growth factor receptor in pancreatic endocrine
Kulke MH. Prospective Study of bevacizumab plus temozolomide tumours. Hum Pathol 2001;32:1184-9.
in patients with advanced neuroendocrine tumors. J Clin Oncol 133. Nilsson O, Wangberg B, Kolby L, Schultz GS, Ahlman H.
2012;l 30:2963-8. Expression of transforming growth factor alpha and its receptor in
121. Yao JC, Phan AT, Fogleman D, Ng CS, Jacobs CB, Dagohoy CD, human neuroendocrine tumours. Int J Cancer 1995;60:645-51.
Leary C, Hess KR. Randomized run-in study of bevacizumab (B) 134. Krishnamurthy S, Dayal Y. Immunohistochemical expression
and everolimus (E) in low- to intermediate-grade neuroendocrine of transforming growth factor alpha and epidermal growth
tumors (LGNETs) using perfusion CT as functional biomarker. J factor receptor in gastrointestinal carcinoids. Am J Surg Pathol
Clin Oncol 2010;28 suppl 15:abstr 4002. 1997;21:327-33.
122. Sonpavde G, Hutson TE. Pazopanib: a novel multitargeted tyrosine 135. Shimizu T, Tanaka S, Haruma K, Kitadai Y, Yoshihara M, Sumii
kinase inhibitor. Curr Oncol Rep 2007;9:115-9. K, Kajiyama G, Shimamoto F. Growth characteristics of rectal
123. Ahn HK, Choi JY, Kim KM, Kim H, Choi SH, Park SH, Park JO, carcinoid tumours. Oncology 2000;59:229-37.
Lim HY, Kang WK, Lee J, Park YS. Phase II study of pazopanib 136. Hobday TJ, Holen K, Donehower RC, Camoriano J, Kim G, Picus
monotherapy in metastatic gastroenteropancreatic neuroendocrine J, Philip P, Lloyd R, Mahoney M, Erlichman C. A phase II trial of
tumours. Br J Cancer 2013;109:1414-9. gefitinib in patients (pts) with progressive metastatic neuroendocrine
124. Phan AT, Yao JC, Fogelman DR, Hess KR, Ng CS, Bullock SA, tumours (NET): a phase II consortium (P2C) study. J Clin Oncol
Malinowski P, Regan E, Kulke M. A prospective, multi-institutional 2006;24:189S. Available from: URL: http://meeting.ascopubs.org/
phase II study of GW786034 (pazopanib) and depot octreotide cgi/content/abstract/24/18_suppl/4043.
(sandostatin LAR) in advanced low-grade neuroendocrine 137. Modlin IM, Shapiro MD, Kidd M. Carcinoid tumor and
carcinoma (LGNEC). Proc Am Soc Clin Oncol 2010;28:abstr 4001. fibrosis: an association with no explanation. Am J Gastroenterol
125. Phan AT, Halperin DM, Chan JA, Hess KR, Malinowski P, Regan 2004;99:2466-78.
E, Ng CS, Yao JC, Kulke MH. Pazopanib and depot octreotide in 138. Yao JC, Zhang JX, Rashid A, Yeung SC, Szklaruk J, Hess K, Xie
advanced, well-differentiated neuroendocrine tumours: a multicentre, K, Ellis L, Abbruzzese JL, Ajani JA. Clinical and in vitro studies
single-group, phase 2 study. Lancet Oncol 2015;16:695-703. of imatinib in advanced carcinoid tumours. Clin Cancer Res
126. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, 2007;13:234-40.
Chen C, Zhang X, Vincent P, McHugh M, Cao Y, Shujath J, Gawlak 139. Lankat-Buttgereit B, Hörsch D, Barth P, Arnold R, Blöcker S,
S, Eveleigh D, Rowley B, Liu L, Adnane L, Lynch M, Auclair D, Göke R. Effects of the tyrosine kinase inhibitor imatinib on
Taylor I, Gedrich R, Voznesensky A, Riedl B, Post LE, Bollag G, neuroendocrine tumour cell growth. Digestion 2005;71:131-40.
Trail PA. BAY 43-9006 exhibits broad spectrum oral antitumour 140. Schott M, Feldkamp J, Lettmann M, Simon D, Scherbaum WA,
activity and targets the RAF/MEK/ERK pathway and receptor Seissler J. Dendritic cell immunotherapy in a neuroendocrine
tyrosine kinases involved in tumour progression and angiogenesis. pancreas carcinoma. Clin Endocrinol (Oxf) 2001;55:271-7.

340
Journal of Cancer Metastasis and Treatment ¦ Volume 2 ¦ August 31, 2016 ¦